Safety of medical interventions in children versus adults

Pediatrics

Volumn 133, Issue 3, 2014, Pages

  Lathyris, Dimitrios ^a   Panagiotou, Orestis A ^b   Baltogianni, Maria ^c   Ioannidis, John P A ^d   Contopoulos Ioannidis, Despina G ^d,e  

^a Gennimatas General Hospital   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e PALO ALTO MEDICAL FOUNDATION RESEARCH INSTITUTE   (United States)

Author keywords

Adults; Children; Comparative safety; Harms; Mortality; Pharmacologic interventions; Withdrawals

Indexed keywords

ADULT; ARTICLE; CHILD; EARLY INTERVENTION; HEALTH CARE; HEALTH HAZARD; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK FACTOR; SAFETY; SYSTEMATIC REVIEW;

ADULTS; CHILDREN; COMPARATIVE SAFETY; HARMS; MORTALITY; PHARMACOLOGIC INTERVENTIONS; WITHDRAWALS;

ADULT; CHILD; EARLY MEDICAL INTERVENTION; HARM REDUCTION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84895175738     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2013-3128     Document Type: Article

References (43)

1. Cohen AL, Budnitz DS, Weidenbach KN, et al. National surveillance of emergency department visits for outpatient adverse drug events in children and adolescents. J Pediatr. 2008;152(3):416-421
2. Holdsworth MT, Fichtl RE, Behta M, et al. Incidence and impact of adverse drug events in pediatric inpatients. Arch Pediatr Adolesc Med . 2003;157(1):60-65 (Pubitemid 36343419)
3. Taché SV, Sönnichsen A, Ashcroft DM. Prevalence of adverse drug events in ambulatory care: a systematic review. Ann Pharmacother. 2011;45(7-8):977-989
4. Choonara I. Safety of new medicines in young children. Arch Dis Child. 2011;96(9):872-873
5. Tullus K. Safety concerns of angiotensin II receptor blockers in preschool children. Arch Dis Child . 2011;96(9):881-882
6. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology -drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157-1167 (Pubitemid 37122329)
7. Posthumus AA, Alingh CC, Zwaan CC, van Grootheest KK, Hanff LL, Witjes BB, et al. Adverse drug reaction-related admissions in paediatrics, a prospective single-centre study. BMJ Open. 2012;2(4):e000934
8. Le J, Nguyen T, Law AV, Hodding J. Adverse drug reactions among children over a 10-year period. Pediatrics. 2006;118(2):555-562 (Pubitemid 46085410)
9. Gallagher RM, Bird KA, Mason JR, et al. Adverse drug reactions causing admission to a paediatric hospital: a pilot study. J Clin Pharm Ther. 2011;36(2):194-199
10. Contopoulos-Ioannidis DG, Baltogianni MS, Ioannidis JP. Comparative effectiveness of medical interventions in adults versus children. J Pediatr. 2010;157(2):322-330. e317
11. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188 (Pubitemid 17189972)
12. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127(9):820-826 (Pubitemid 27465551)
13. Orsini N, Bottai M, Higgins J, Buchan I. HETEROGI: Stata module to quantify herterogeneity in a meta-analysis. EconPapers. Available at: http://econpapers.repec.org/software/bocbocode/s449201.htm Accessed January 2013
14. Ioannidis JP, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ. 2007;335(7626):914-916 (Pubitemid 350076978)
15. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558 (Pubitemid 34746062)
16. Bourgeois FT, Murthy S, Pinto C, Olson KL, Ioannidis JP, Mandl KD. Pediatric versus adult drug trials for conditions with high pediatric disease burden. Pediatrics. 2012;130(2):285-292
17. Boots I, Sukhai RN, Klein RH, et al. Stimulation programs for pediatric drug research-do children really benefit? Eur J Pediatr. 2007;166(8):849-855 (Pubitemid 46988181)
18. Sachs AN, Avant D, Lee CS, Rodriguez W, Murphy MD. Pediatric information in drug product labeling. JAMA. 2012;307(18):1914-1915
19. Shah SS, Hall M, Goodman DM, et al. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med. 2007;161(3):282-290 (Pubitemid 46364332)
20. Ballard CD, Peterson GM, Thompson AJ, Beggs SA. Off-label use of medicines in paediatric inpatients at an Australian teaching hospital. J Paediatr Child Health. 2013;49(1):38-42
21. Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr. 2005;164(9):552-558
22. Fontanarosa PB, Rennie D, DeAngelis CD. Postmarketing surveillance-lack of vigilance, lack of trust. JAMA. 2004;292(21):2647-2650 (Pubitemid 39577521)
23. Lloyd-Johnsen C, Justice F, Donath S, Bines JE. Retrospective hospital based surveillance of intussusception in children in a sentinel paediatric hospital: benefits and pitfalls for use in post-marketing surveillance of rotavirus vaccines. Vaccine. 2012;30(suppl 1):A190- A195
24. Benjamin DK Jr, Smith PB, Murphy MD, et al. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA. 2006;296(10):1266- 1273 (Pubitemid 44394898)
25. Buttery JP, Danchin MH, Lee KJ, et al PAEDS/APSU Study Group. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine. 2011;29(16):3061-3066
26. Ioannidis JP. Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Arch Intern Med. 2009;169(19):1737-1739
27. Ioannidis JP, Contopoulos-Ioannidis DG. Reporting of safety data from randomised trials. Lancet. 1998;352(9142):1752-1753 (Pubitemid 28534962)
28. Nuovo J, Sather C. Reporting adverse events in randomized controlled trials. Pharmacoepidemiol Drug Saf. 2007;16(3):349-351 (Pubitemid 46431697)
29. Anderson M, Choonara I. A systematic review of safety monitoring and drug toxicity in published randomised controlled trials of antiepileptic drugs in children over a 10-year period. Arch Dis Child. 2010;95(9):731-738
30. Sammons HM, Gray C, Hudson H, Cherrill J, Choonara I. Safety in paediatric clinical trials-a 7-year review. Acta Paediatr. 2008;97(4):474 -477
31. Nor Aripin KN, Choonara I, Sammons HM. Systematic review of safety in paediatric drug trials published in 2007. Eur J Clin Pharmacol. 2012;68(2):189-194
32. Ioannidis JP, Evans SJ, Gøtzsche PC, et al CONSORT Group. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141(10):781-788 (Pubitemid 39524916)
33. Barbour V, Clark J, Jones S, Norton M, Simpson P, Veitch E. Why drug safety should not take a back seat to efficacy. PLoS Med. 2011;8(9):e1001097
34. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001;285(4):437-443 (Pubitemid 32097262)
35. Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med. 2009;169(19):1756-1761
36. Tsang R, Colley L, Lynd LD. Inadequate statistical power to detect clinically significant differences in adverse event rates in randomized controlled trials. J Clin Epidemiol. 2009;62(6):609-616
37. Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med. 2011;8(5):e1001026
38. Hernandez AV, Walker E, Ioannidis JP, Kattan MW. Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone. Am Heart J. 2008;156(1):23-30
39. Papanikolaou PN, Ioannidis JP. Availability of large-scale evidence on specific harms from systematic reviews of randomized trials. Am J Med. 2004;117(8):582-589 (Pubitemid 39304209)
40. Contopoulos-Ioannidis DG, Seto I, Hamm MP, et al. Empirical evaluation of age groups and age-subgroup analyses in pediatric randomized trials and pediatric meta-analyses. Pediatrics. 2012;129(suppl 3):S161-S184
41. Williams K, Thomson D, Seto I, et al; StaR Child Health Group. Standard 6: age groups for pediatric trials. Pediatrics. 2012;129(suppl 3):S153-S160
42. Anderson BJ. Developmental pharmacology; filling one knowledge gap in pediatric anesthesiology. Paediatr Anaesth. 2011;21(3):179-182
43. Klassen TP, Hartling L, Craig JC, Offringa M. Children are not just small adults: the urgent need for high-quality trial evidence in children. PLoS Med. 2008;5(8):e172